A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus

StatusCompleted
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Final enrollment: 3 participants — 9% of the 34 planned Show 5 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Sep 30, 2027 to Jun 6, 2026
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 20, 2024 to Jan 8, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory systemic lupus erythematosus.
Trial Details
NCT Number NCT06653556
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Nanjing Legend Biotech Co., Beijing GoBroad Hospital
Conditions
(from sponsor)		 Systemic Lupus Erythematosus (SLE)
Related terms Anemia, Hemolytic, Autoimmune, Hypertension, Pulmonary, Lupus Erythematosus, Systemic, Lupus Nephritis, Recurrence
Enrollment 3 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov